App-Quantinova.ai

Risk Factors and Outcomes of Deep Vein Thrombosis in Pediatric Osteomyelitis

Maria Ahmad - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism

Tareq Abu Assab - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

F5 Sequence Variant Identified in 7 Patients Evaluated for Hypercoagulable State with a Factor V (FV) HR2 Assay

Margaret M. Leech - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Outcomes in the Secondary Prevention of Cerebral Venous Thrombosis in Cancer Only Population

Nadia Isabel Abelhad - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Venous Thromboembolic Disease and Bone Marrow Transplant: A Remarkable Cause of Mortality and Morbidity — Potentially Preventable

Marta Rivas Luque - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients

Graham McIlroy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

rivaroxaban

Factors Associated with Bleeding Events in Patients Receiving Rivaroxaban for Venous Thromboembolism: A Real World Experience

Ankit Mangla - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rivaroxaban

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

Gregorio Campos-Cabrera - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Erythropoietin

Venous Thromboembolism Events and Prophylaxis in Patients with Acute Myeloid Leukemia

Daniel R Reed - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon

Habib El-Khoury - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Dexamethasone

Compound Application of Thalidomide and Recombinant Human Interferon-α-1b, Interleukin-2 in Different Disease Status of Acute Myeloid Leukemia a Multi-Center Prospective Study of a New Combination of Old Drugs

Lin Chen - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Interferon alpha

Thalidomide Combined with Interferons for the Treatment of Recurrent or Refractory Non-Hodgkin's Lymphoma

Fangfang Yuan - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Thalidomide

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®

Jeffrey A Gilreath - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Peginterferon alfa-2a

Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Jacki Day - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Warfarin

Januskinase-2 V617F Positive Myeloproliferative Neoplasms and Haemostatic Disorders: Importance of Obesity in Prediction of Thrombotic Events

Marta Pires De Lima - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

A Study about the Relationship between Thrombotic Events and Peripheral Neutrophil-to-Lymphocyte Ratio in Patients with Newly Diagnosed Essential Thrombocythemia

Hai Cheng - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Incidence of Silent Thrombosis in Myeloproliferative Neoplasm Patients below 60 Years : Single Center Egyptian Study

Mervat Mattar - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Incorporation of Clinical Information to Decipher Driver Mutations in Myeloproliferative Neoplasms

Murtadha K. Al-Khabori - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Erythropoietin

Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort

Sofia Chiatamone Ricci - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Kiran Naqvi - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Lenalidomide

Filters

7277 Abstracts